



Oregon Health & Science University
Hospital and Clinics Provider's Orders

PO7071



ADULT AMBULATORY INFUSION ORDER
inFLIXimab
(INFLECTRA, REMICADE)

Page 1 of 4

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

Weight: _____ kg Height: _____ cm

Allergies: _____

Diagnosis Code: _____

Treatment Start Date: _____ Patient to follow up with provider on date: _____

****This plan will expire after 365 days at which time a new order will need to be placed****

GUIDELINES FOR ORDERING

1. Send **FACE SHEET and H&P or most recent chart note.**
2. A Tuberculin test must have been placed and read as negative within the past year (PPD or QuantiFERON Gold blood test).
3. Hepatitis B (Hep B surface antigen and core antibody) screening must be completed prior to initiation of therapy and the patient should not be infected.
4. Patients should not have an active ongoing infection, signs or symptoms of malignancy, or moderate to severe heart failure at the onset of TNF-alpha inhibitor therapy. Baseline liver function tests should be normal.
5. Patient should have regular monitoring for TB, hepatitis B, infection, malignancy, and liver abnormalities throughout therapy.

OTHER:

- Tuberculin (TUBERSOL, APLISOL) injection, 5 units, intradermal, ONCE, Perform prior to initiation of TNF-alpha inhibitor therapy

PRE-SCREENING: (Results must be available prior to initiation of therapy):

- Hepatitis B Surface AG, serum, Routine, ONCE
- Hepatitis B Core AB Qual, serum, Routine, ONCE

OR

- Hepatitis B surface antigen and core antibody test results scanned with orders

- Tuberculin Test Result. Date: _____ Positive / Negative

LABS:

- Antinuclear antibody screening, Routine, ONCE, prior to initiation of TNF-alpha inhibitor therapy
- Basic Metabolic Set, Routine, ONCE, every _____ (visit)(days)(weeks)(months) – Circle One
- CBC with differential, Routine, ONCE, every _____ (visit)(days)(weeks)(months) – Circle One
- Liver Set (AST, ALT, BILI TOTAL, BILI DIRECT, ALK PHOS, ALB, PROT TOTAL), Routine, ONCE, every _____ (visit)(days)(weeks)(months) – Circle One
- HCG Beta, PLASMA, routine, ONCE, every _____ (visit)(days)(weeks)(months) – Circle One
- Labs already drawn. Date: _____



Oregon Health & Science University
Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER
inFLIXimab
(INFLECTRA, REMICADE)

Page 2 of 4

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

PRE-MEDICATIONS: (Administer 30 minutes prior to infusion)

Note to provider: Please select which medications below, if any, you would like the patient to receive prior to treatment by checking the appropriate box(s)

- acetaminophen (TYLENOL) tablet, oral, ONCE, every visit
 - 325 mg
 - 650 mg
 - 500 mg
 - 1000 mg
- diphenhydrAMINE (BENADRYL) capsule, oral, ONCE, every visit
 - 25 mg
 - 50 mg
- loratadine (CLARITIN) tablet, oral, ONCE, every visit
(Choose as alternative to diphenhydrAMINE if needed)
 - 5 mg
 - 10 mg
- methylPREDNISolone sodium succinate (SOLU-MEDROL), 40 mg, intravenous, ONCE, every visit
(Choose if patient has required IV steroids for a reaction during a prior TNF-alpha inhibitor infusion)

MEDICATIONS:

Biosimilar selection (must check one) – applies to all orders below

- INFLECTRA (inFLIXimab-dyyb) ****preferred formulary agent****
- REMICADE (inFLIXimab)

Initial Doses: (Pharmacist will use most recent weight and round dose to the nearest 100 mg vial)

- 3 mg/kg in NaCl 0.9%, intravenous
- 5 mg/kg in NaCl 0.9%, intravenous
- 10 mg/kg in NaCl 0.9%, intravenous

Interval: (must check one)

- Once
- Three doses at 0, 2, and 6 weeks; dates: Week 0_____, Week 2_____, Week 6_____
- Other: _____

Maintenance Doses: (Pharmacist will use most recent weight and round dose to nearest 100 mg vial)

- 3 mg/kg in NaCl 0.9%, intravenous
- 5 mg/kg in NaCl 0.9%, intravenous
- 10 mg/kg in NaCl 0.9%, intravenous

Interval:

- Every _____ weeks for _____ doses



Oregon Health & Science University
Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER
inFLIXimab
(INFLECTRA, REMICADE)

Page 3 of 4

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

NURSING ORDERS:

1. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.
2. Infuse over at least 2 hours. Begin infusion at 10 mL/hr for 15 minutes, then double rate every 15 minutes during first hour. After 1 hour may increase to 250 mL/hr.
3. Monitor and record vital signs, tolerance, and presence of infusion-related reactions prior to infusion, then every 15 minutes x 30 minutes, then every 30 minutes until infusion is completed. Consider observing patient for 60 minute following infusion.

HYPERSENSITIVITY MEDICATIONS:

1. If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (Policy HC-PAT-133-GUD). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
2. diphenhydrAMINE (BENADRYL) injection, 25 mg, intravenous, AS NEEDED x2 doses for hypersensitivity reaction, Max dose 50 mg
3. EPINEPHrine HCl (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x1 dose for hypersensitivity reaction
4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity reaction

AS NEEDED MEDICATIONS:

1. acetaminophen (TYLENOL) tablet, 650 mg, oral, EVERY 4 HOURS AS NEEDED for fever
2. diphenhydrAMINE (BENADRYL) capsule, 25 mg, oral, EVERY 4 HOURS AS NEEDED for itching
3. sodium chloride 0.9% solution, intravenous, 500mL, AS NEEDED x1 dose, for TNF-alpha inhibitor infusion tolerability. Give concurrently with TNF-alpha inhibitor

By signing below, I represent the following:

I am responsible for the care of the patient (*who is identified at the top of this form*);

I hold an active, unrestricted license to practice medicine in: Oregon _____ (*check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon*);

My physician license Number is # _____ (MUST BE COMPLETED TO BE A VALID PRESCRIPTION); and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.

Provider signature: _____ Date/Time: _____

Printed Name: _____ Phone: _____ Fax: _____



Oregon Health & Science University
Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER
inFLIXimab
(INFLECTRA, REMICADE)

Page 4 of 4

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

OLC Central Intake Nurse:

Phone: 971-262-9645 (providers only) Fax: 503-346-8058

Please check the appropriate box for the patient's preferred clinic location:

Beaverton

OHSU Knight Cancer Institute
15700 SW Greystone Court
Beaverton, OR 97006

Phone number: 971-262-9000

Fax number: 503-346-8058

NW Portland

Legacy Good Samaritan campus
Medical Office Building 3, Suite 150
1130 NW 22nd Ave.
Portland, OR 97210

Phone number: 971-262-9600

Fax number: 503-346-8058

Gresham

Legacy Mount Hood campus
Medical Office Building 3, Suite 140
24988 SE Stark
Gresham, OR 97030

Phone number: 971-262-9500

Fax number: 503-346-8058

Tualatin

Legacy Meridian Park campus
Medical Office Building 2, Suite 140
19260 SW 65th Ave.
Tualatin, OR 97062

Phone number: 971-262-9700

Fax number: 503-346-8058

Infusion orders located at: www.ohsuknight.com/infusionorders